Security
CytomX Therapeutics, Inc. Common Stock · CTMX
CTMXNASDAQCommon stockCurrentCIK 1501989Updated Oct 29, 2026
CTMX price & chart
Loading TradingView…
NASDAQ:CTMX on TradingView ↗About the company
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked PROBODY® therapeutics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), cytokines and T-cell engagers. CytomX’s clinical-stage pipeline includes varsetatug masetecan (Varseta-M; CX-2051) and CX-801. Varseta-M is a masked, conditionally activated ADC armed with a topoisomerase-1 inhibitor payload and directed toward epithelial cell adhesion molecule (EpCAM). EpCAM is a highly expressed tumor antigen that has previously been undruggable due to expression on normal tissues. Varseta-M is designed to open a therapeutic window for this high potential target and is initially being developed for the treatment of metastatic colorectal cancer. Varseta-M was discovered in collaboration with ImmunoGen, now part of Ab…
In the news
CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026 ↗
A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs ↗
Seeking Alpha
CytomX Therapeutics, Inc. (CTMX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript ↗
CytomX Therapeutics, Inc. (CTMX) Presents at Wells Fargo 21st Annual Healthcare Conference - Slideshow ↗
CytomX gains Fast Track status for colorectal cancer antibody-drug conjugate ↗
Recent filings
SCHEDULE 13G/A - filed by BANK OF AMERICA CORP /DE/ regarding CytomX Therapeutics, Inc.
SCHEDULE 13G/A - filed by Point72 Asset Management, L.P. regarding CytomX Therapeutics, Inc.
SCHEDULE 13G/A - filed by Kynam Capital Management, LP regarding CytomX Therapeutics, Inc.
S-8 filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
10-Q filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.03, 5.07, 9.01
4 filing
Entry into a Material Definitive Agreement
Items 1.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 158,254,000Source | 138,981,000Source | 381,226,000Source | 175,057,000Source | 159,219,000Source | 359,358,000Source | 98,497,000Source | 184,687,000Source | 151,566,000Source | 120,533,000Source | 201,792,000Source | 260,891,000Source |
| Property, Plant and Equipment, NetUSD | 1,721,000Source | 2,942,000Source | 1,079,000Source | 1,946,000Source | 3,316,000Source | 1,090,000Source | 2,229,000Source | 3,567,000Source | 1,304,000Source | 2,467,000Source | 3,958,000Source | 5,072,000Source |
| GoodwillUSD | 949,000Source | 949,000Source | 949,000Source | 949,000Source | 949,000Source | 949,000Source | 949,000Source | 949,000Source | 949,000Source | 949,000Source | 949,000Source | 949,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 34,185,000Source | 40,576,000Source | 17,224,000Source | 49,041,000Source | 43,247,000Source | 28,828,000Source | 47,604,000Source | 36,185,000Source | 12,667,000Source | 38,052,000Source | 17,171,000Source | 193,650,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 1,629,000Source | 3,352,000Source | 37,494,000Source | 1,869,000Source | 2,775,000Source | 646,000Source | 1,956,000Source | 13,177,000Source | 2,013,000Source | 3,103,000Source | 3,432,000Source | 35,986,000Source |
| Assets, CurrentUSD | 149,217,000Source | 124,180,000Source | 373,155,000Source | 164,621,000Source | 143,080,000Source | 353,096,000Source | 86,628,000Source | 167,247,000Source | 143,921,000Source | 107,305,000Source | 182,936,000Source | 237,102,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,962,000Source | 3,240,000Source | 4,464,000Source | 4,665,000Source | 3,123,000Source | 5,743,000Source | 4,786,000Source | 3,786,000Source | 4,856,000Source | 3,579,000Source | 4,995,000Source | 7,466,000Source |
| Operating Lease, Right-of-Use AssetUSD | 4,814,000Source | 9,193,000Source | 5,037,000Source | 5,947,000Source | 10,225,000Source | 2,264,000Source | 7,055,000Source | 11,234,000Source | 3,396,000Source | 8,136,000Source | 12,220,000Source | 15,949,000Source |
| Other Assets, NoncurrentUSD | 51,000Source | 70,000Source | 31,000Source | 56,000Source | 76,000Source | 31,000Source | 61,000Source | 80,000Source | 31,000Source | 66,000Source | 83,000Source | 27,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 50,865,000Source | 162,433,000Source | 79,158,000Source | 55,147,000Source | 190,446,000Source | 39,414,000Source | 73,448,000Source | 216,367,000Source | 52,558,000Source | 120,989,000Source | 249,239,000Source | 346,642,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | — | — |
| Common Stock, Value, IssuedUSD | 2,000Source | 1,000Source | 2,000Source | 2,000Source | 1,000Source | 2,000Source | 1,000Source | 1,000Source | 2,000Source | 1,000Source | 1,000Source | 1,000Source |
| Additional Paid in CapitalUSD | 789,720,000Source | 686,962,000Source | 1,053,125,000Source | 788,083,000Source | 684,967,000Source | 1,050,037,000Source | 693,103,000Source | 677,986,000Source | 810,844,000Source | 691,095,000Source | 675,905,000Source | 637,117,000Source |
| Retained Earnings (Accumulated Deficit)USD | -682,437,000Source | -710,455,000Source | -750,863,000Source | -668,208,000Source | -716,191,000Source | -730,197,000Source | -668,054,000Source | -709,657,000Source | -711,949,000Source | -691,579,000Source | -723,448,000Source | -722,879,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 104,000Source | 40,000Source | -196,000Source | 33,000Source | -4,000Source | 102,000Source | -1,000Source | -10,000Source | 111,000Source | 27,000Source | 95,000Source | 10,000Source |
| Stockholders' Equity Attributable to ParentUSD | 107,389,000Source | -23,452,000Source | 302,068,000Source | 119,910,000Source | -31,227,000Source | 319,944,000Source | 25,049,000Source | -31,680,000Source | 99,008,000Source | -456,000Source | -47,447,000Source | -85,751,000Source |
| Liabilities and EquityUSD | 158,254,000Source | 138,981,000Source | 381,226,000Source | 175,057,000Source | 159,219,000Source | 359,358,000Source | 98,497,000Source | 184,687,000Source | 151,566,000Source | 120,533,000Source | 201,792,000Source | 260,891,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 41,029,000Source | 119,228,000Source | 39,861,000Source | 39,223,000Source | 142,858,000Source | 34,023,000Source | 50,201,000Source | 144,536,000Source | 46,615,000Source | 85,772,000Source | 155,913,000Source | 152,608,000Source |
| Operating Lease, Liability, CurrentUSD | 5,596,000Source | 5,001,000Source | 1,496,000Source | 5,443,000Source | 4,861,000Source | 2,856,000Source | 5,293,000Source | 4,724,000Source | 4,240,000Source | 5,145,000Source | 4,589,000Source | 4,082,000Source |
| Accounts Payable, CurrentUSD | 646,000Source | 1,422,000Source | 1,939,000Source | 227,000Source | 611,000Source | 1,368,000Source | 276,000Source | 1,964,000Source | 1,301,000Source | 1,088,000Source | 1,458,000Source | 2,809,000Source |
| Operating Lease, Liability, NoncurrentUSD | 0Source | 5,596,000Source | 4,208,000Source | 1,442,000Source | 6,885,000Source | — | 2,856,000Source | 8,148,000Source | 0Source | 4,240,000Source | 9,385,000Source | 13,975,000Source |
| Other Liabilities, NoncurrentUSD | 4,299,000Source | 4,053,000Source | 4,472,000Source | 4,241,000Source | 3,993,000Source | 4,412,000Source | 4,177,000Source | 3,940,000Source | 4,353,000Source | 4,115,000Source | 3,893,000Source | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 12,408,000Source | 16,742,000Source | 12,353,000Source | 11,503,000Source | 13,620,000Source | 11,923,000Source | 11,406,000Source | 14,220,000Source | 14,197,000Source | 12,338,000Source | 17,599,000Source | 28,532,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | 118,628,000Source | — | — | 138,190,000Source | — | 79,900,000Source | 154,085,000Source | — | 101,870,000Source | 175,364,000Source | 95,574,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -18,248,000Source | 23,525,000Source | -17,368,000Source | 31,869,000Source | -569,000Source | -99,317,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 4,706,000Source | 2,008,000Source | 6,302,000Source | 7,668,000Source | 8,558,000Source | 13,125,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -1,367,000Source | -1,147,000Source | -1,090,000Source | -329,000Source | -32,554,000Source | 35,196,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 67,000Source | -804,000Source | 221,000Source | -297,000Source | -1,426,000Source | 68,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -25,549,000Source | -21,043,000Source | -75,587,000Source | -86,231,000Source | -56,035,000Source | -110,788,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -192,777,000Source | 30,596,000Source | -59,744,000Source | 99,700,000Source | -150,674,000Source | 98,260,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 0Source | 119,000Source | 220,000Source | 310,000Source | 840,000Source | 1,740,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 234,487,000Source | 0Source | 110,446,000Source | 7,522,000Source | 30,230,000Source | 648,000Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 37,000Source | 36,000Source | 146,000Source | 146,000Source | 146,000Source | 146,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | 118,628,000Source | — | — | — | 79,900,000Source | — | 101,870,000Source | 175,364,000Source | 95,574,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 1,200,000Source | 1,600,000Source | 2,000,000Source | 2,300,000Source |
| Gain (Loss) on Sale of Assets and Asset Impairment ChargesUSD | — | — | — | — | — | — | — | — | -402,000Source | -106,000Source | 0Source | -254,000Source |
| General and Administrative ExpenseUSD | — | — | 6,427,000Source | 7,953,000Source | 7,601,000Source | 6,622,000Source | 10,692,000Source | 9,428,000Source | 29,837,000Source | 29,726,000Source | 30,018,000Source | 42,849,000Source |
| GoodwillUSD | — | — | 949,000Source | 949,000Source | 949,000Source | 949,000Source | 949,000Source | 949,000Source | 949,000Source | 949,000Source | 949,000Source | 949,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | — | — | 58,000Source | 61,000Source | 60,000Source | 63,000Source | 59,000Source | 62,000Source | 238,000Source | 224,000Source | 3,892,000Source | 0Source |
| Investment Income, InterestUSD | — | — | 1,592,000Source | 1,693,000Source | 3,157,000Source | 1,178,000Source | 1,490,000Source | 955,000Source | 5,206,000Source | 7,136,000Source | 9,837,000Source | 1,678,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -14,229,000Source | 5,736,000Source | -20,666,000Source | -154,000Source | -18,248,000Source | 23,525,000Source | -17,368,000Source | 31,869,000Source | -569,000Source | -99,317,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | -20,666,000Source | -154,000Source | -18,248,000Source | 23,525,000Source | -20,370,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 21,731,000Source | 29,321,000Source | 25,199,000Source | 19,944,000Source | 29,930,000Source | 28,296,000Source | 98,565,000Source | 113,108,000Source | 107,698,000Source | 154,498,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | 5,100,000Source | 5,100,000Source | 5,100,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 5,000Source | -7,000Source | 18,000Source | 17,000Source | -7,000Source | 11,000Source | 28,000Source | -38,000Source | -30,000Source | 340,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 234,200,000Source | 0Source | 109,635,000Source | 6,909,000Source | — | 0Source |
| Restructuring CostsUSD | — | — | — | — | — | 25,000Source | — | — | — | — | — | 7,700,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 5,963,000Source | 33,432,000Source | 1,418,000Source | 18,658,000Source | 10,258,000Source | 50,917,000Source | 76,201,000Source | 138,103,000Source | 101,214,000Source | 53,163,000Source |
| Operating Income (Loss)USD | — | — | -15,768,000Source | 4,111,000Source | -23,781,000Source | -1,286,000Source | -19,672,000Source | 22,621,000Source | -22,364,000Source | 24,995,000Source | -6,484,000Source | -101,335,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 5,000Source | -7,000Source | 18,000Source | 17,000Source | -7,000Source | 11,000Source | 28,000Source | -38,000Source | -30,000Source | 340,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -14,171,000Source | 5,797,000Source | -20,606,000Source | -91,000Source | -18,189,000Source | 23,587,000Source | -17,130,000Source | 32,093,000Source | 3,323,000Source | -99,317,000Source |
| Income Tax Expense (Benefit)USD | — | — | 58,000Source | 61,000Source | 60,000Source | 63,000Source | 59,000Source | 62,000Source | 238,000Source | 224,000Source | 3,892,000Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -14,229,000Source | 5,736,000Source | -20,666,000Source | -154,000Source | -18,248,000Source | 23,525,000Source | -17,368,000Source | 31,869,000Source | -569,000Source | -99,317,000Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 165,004,291Source | 85,093,227Source | 218,939,423Source | 129,075,546Source | 177,273,000Source | 87,121,502Source | 137,935,873Source | 84,439,303Source | 73,808,237Source | 65,739,844Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 165,004,291Source | 85,204,709Source | 218,939,423Source | 129,075,546Source | 177,273,000Source | 87,150,666Source | 137,935,873Source | 84,745,116Source | 73,808,237Source | 65,739,844Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 37,000Source | 36,000Source | 146,000Source | 146,000Source | 146,000Source | 146,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 238,000Source | 224,000Source | 3,892,000Source | — |
| General and Administrative ExpenseUSD | — | — | 6,427,000Source | 7,953,000Source | 7,601,000Source | 6,622,000Source | 10,692,000Source | 9,428,000Source | 29,837,000Source | 29,726,000Source | 30,018,000Source | 42,849,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | -0.09Source | 0.07Source | -0.09Source | 0Source | -0.1Source | 0.27Source | -0.15Source | 0.38Source | -0.01Source | -1.51Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | -0.09Source | 0.07Source | -0.09Source | 0Source | -0.1Source | 0.27Source | -0.15Source | 0.38Source | -0.01Source | -1.51Source |
| Investment Income, InterestUSD | — | — | 1,592,000Source | 1,693,000Source | 3,157,000Source | 1,178,000Source | 1,490,000Source | 955,000Source | 5,206,000Source | 7,136,000Source | 9,837,000Source | 1,678,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | -20,666,000Source | -154,000Source | -18,248,000Source | 23,525,000Source | -20,370,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 21,731,000Source | 29,321,000Source | 25,199,000Source | 19,944,000Source | 29,930,000Source | 28,296,000Source | 98,565,000Source | 113,108,000Source | 107,698,000Source | 154,498,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | 5,100,000Source | 5,100,000Source | 5,100,000Source |
| Research and Development ExpenseUSD | — | — | 15,304,000Source | 21,368,000Source | 17,598,000Source | 13,322,000Source | 19,238,000Source | 18,868,000Source | 68,728,000Source | 83,382,000Source | 77,680,000Source | 111,649,000Source |
| Restructuring CostsUSD | — | — | — | — | — | 25,000Source | — | — | — | — | — | 7,700,000Source |
Offerings
Registration 333-294342
Filing attachments
ctmx-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 ctmx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update Varsetatug masetecan (“Varseta-M”) Program: - Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 - - Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing. Phase 1/2 chemotherapy combination study focused in 2L mCRC initiating in Q4 2026 - -…
Read attachment ↗ctmx-ex99_1.htm · 8-K · 2026-05-07
EX-99.1 2 ctmx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update - Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - Enrollment of 40 patients in Varseta-M Dose Optimization completed; data update expected in 2H 2026 to inform monotherapy dose selection and potential registrational trial in late …
Read attachment ↗d100765dex41.htm · 8-K · 2026-03-19
EX-4.1 3 d100765dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: __________ (subject to adjustment) Warrant No. _____ Original Issue Date: __________, 2026 CytomX Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, __________ or its registered assigns (the “Holder”), is entitled, subject to the terms…
Read attachment ↗d60825dex46.htm · S-3ASR · 2026-03-16
Exhibit 4.6 CytomX Therapeutics, Inc. INDENTURE Dated as of [___], 20[__] [___] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions …
Read attachment ↗ctmx-ex99_1.htm · 8-K · 2026-03-16
EX-99.1 2 ctmx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update - Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted for mid-year with goal to align on potential Varseta-M registrational trial design in late line CRC - - Varseta-M Phase 1 study evaluating combination with …
Read attachment ↗ctmx-ex4_4.htm · 10-K · 2026-03-16
Exhibit 4.4 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of the securities of CytomX Therapeutics, Inc. (“we,” “us” or “our”) that are registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following description of our securities is not complete and may not contain all the information you should consider before investing in o…
Read attachment ↗